How challenging can it be to treat Behcet uveitis?


ORAY M., CEBECİ Z., KIR N., Tugal-Tutkun I.

SAUDI JOURNAL OF OPHTHALMOLOGY, vol.36, no.4, pp.397-399, 2022 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 36 Issue: 4
  • Publication Date: 2022
  • Doi Number: 10.4103/sjopt.sjopt_74_22
  • Journal Name: SAUDI JOURNAL OF OPHTHALMOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, EMBASE
  • Page Numbers: pp.397-399
  • Istanbul University Affiliated: Yes

Abstract

A 20-year-old male Behcet uveitis (BU) patient presented with visual acuities (VAs) of hand movement in OD and counting fingers at 1 m in OS following treatment with corticosteroid monotherapy elsewhere. He had active intraocular inflammation OU along with macular hole and retinal detachment in OS. Infliximab (IFX) was started and vitreoretinal surgery was performed. He had infusion reaction with IFX, hepatotoxicity and depression with interferon, and resistance to adalimumab and tocilizumab therapies. Cytomegalovirus retinitis developed in OD following intravitreal dexamethasone implant and endophthalmitis developed in OS. At the 33(rd) month of follow-up, the patient was in clinical remission; however, there was persistent angiographic inflammation under certolizumab pegol, cyclosporine, mycophenolate mofetil, and low-dose prednisolone treatment. The left eye was phthisical and VA was 0.4 in OD. Immunomodulatory treatment is given based on the severity of inflammation in BU and needs to be closely monitored for efficacy and adverse effects.